在心力衰竭患者中,心脏结构和功能与减少喷射分数和病患者的心脏结构和功能
Ali Hikmat Al-Rubai1,2,3, Jacob Christensen1,2,3, Filip Soeskov Davidovski1,2,3
1Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
Echocardiography (Mount Kisco, N.Y.)
|November 17, 2025
概括
患有病 (KD) 的心力衰竭与减少喷射率 (HFrEF) 患者表现出心脏功能受损. 左心室喷射率 (LVEF) 等心声测量措施可以预测未来的KD发病.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 医疗成像医学成像
背景情况:
- 病 (KD) 是患有心力衰竭与减少喷射率 (HFrEF) 的患者经常出现的并发症.
- 了解心脏结构/功能和KD之间的关系对于管理HFrEF患者至关重要.
研究的目的:
- 在HFrEF患者中调查心脏结构和功能测量与流行和发病病相关的情况.
- 在这个人群中确定脏疾病发展的心声学预测因子.
主要方法:
- 对1138名HFrEF患者的回顾性分析 (左心室喷射率≤45%).
- 患者分为多层次的组:没有KD,事件KD和流行KD.
- 评估的心声学参数:LVEF,全球纵向应变 (GLS),三环状平面缩外流 (TAPSE) 和E/e'比.
- 考克斯回归分析用于评估与事件KD的关联.
主要成果:
- 在基线时,在KD严重程度组中观察到LVEF,GLS,TAPSE和E/e'比率受损.
- 在无变量分析中,所有四个心声回声测量都与发生的KD有关.
- 在调整后,LVEF,TAPSE和E/e'比仍然是事件KD的重要预测指标.
结论:
- 通过GLS,LVEF,TAPSE和E/e'比率评估的心脏功能障碍与HFrEF患者的流行和发病KD有关.
- LVEF,TAPSE和E/e'比率是事件KD的独立预测指标,突出了它们的预后价值.
相关概念视频
01:22Heart Failure Drugs: Diuretics
763
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
763
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:27Heart Failure I: Introduction
653
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
653
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869